Kures
Cara Baugh serves as a Member of the Board of Directors for Kures and Psyber since 2023 and holds the position of Senior Director and Associate General Counsel at atai Life Sciences from August 2021 to present. Prior roles include Deputy Corporate & Compliance Counsel at Hercules Pharmaceuticals, Inc. (2019-2020) and Partner in Corporate, Securities, and Cannabis Law Groups at Abrams, Fensterman, Fensterman, Eisman, Formato, Ferrara, Wolf & Carone, LLP (2013-2016). Previous experience also includes Associate General Counsel at Marcum LLP (2010-2013), Senior Associate in M&A, Corporate and Securities Law at Davidoff Hutcher & Citron LLP (2006-2010), and Regulatory and Compliance Associate at Lehman & Eilen LLP (2003-2005). Early career began as an Associate focusing on Financial Services, Broker Dealer, and Hedge Funds at Katten Muchin Rosenman LLP (2001-2002). Cara Baugh earned a Juris Doctor from Fordham University School of Law and a Bachelor of Arts in Psychology, Sociology, and Art History from the University at Albany, with additional studies at London Metropolitan University.
This person is not in the org chart
This person is not in any teams
Kures
Kures is a pre-clinical-stage biopharmaceutical startup that develops opioid-based treatments for depressive disorder.The biopharmaceutical company is also interested in addressing other challenging indications in the psychiatry and physical pain arena using its portfolio of novel small molecules. It is currently operating in Stealth mode.Andrew Kruegel established the biotech company in 2017 in Dobbs Ferry, New York.